Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

nary hemorrhage (1).

Clinical development of XL999 was re-initiated in April 2007. This clinical trial will evaluate XL999 in patients with NSCLC who have failed at least one previous therapy. The trial will have a dose-escalation format starting at 0.4 mg/kg dosed weekly, while monitoring patients for potential cardiovascular events. Results from this Phase I clinical trial could provide Exelixis with the opportunity to move directly into a late stage clinical trial if XL999 demonstrates anti-tumor activity with an acceptable side-effect profile in this well-defined NSCLC patient population. Exelixis expects to begin enrolling patients in this trial during the summer of 2007.

(Back to top)

About XL999

XL999 is a potent inhibitor of key receptor tyrosine kinases implicated in the development and maintenance of tumor vasculature, and in the proliferation of some tumor cells. It inhibits FGFR1, FGFR3, RET, VEGFR2, and PDGFR. The compound is also a potent inhibitor of FLT3, an important driver of leukemia cell proliferation in some patients with acute myelogenous leukemia (AML). XL999 exhibited potent activity in preclinical target-specific pharmacodynamic models, as well as efficacy models for solid tumors and for FLT3-driven leukemia.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyet
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/17/2009)... Dec. 17 Frost & Sullivan ... American Healthcare Innovation Award in molecular diagnostics ... its commitment to providing innovative technologies for ... its incorporation in 2004, IntelligentMDx has introduced ... to make tests that are clinically impactful, ...
(Date:12/17/2009)... Mass., Dec. 17 Decision Resources, one ... focusing on pharmaceutical and healthcare issues, finds that ... there is a high need for diabetes drugs ... who say there is a high need for ... favor agents with excellent glucose lowering ability and ...
(Date:12/16/2009)... Dec. 17 Cell Therapeutics, Inc. ... that on February 10, 2010 the U.S. ... Committee (ODAC) will review the New Drug ... of relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC ... evaluates data concerning the efficacy and safety ...
Breaking Medicine Technology:Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Senator Proposes Use of Internet Gambling Revenue to Help Fund Health Care Reform 57860 1Senator Proposes Use of Internet Gambling Revenue to Help Fund Health Care Reform 57860 2New Report Highlights Proven Disease Prevention Programs in Communities 57858 1New Report Highlights Proven Disease Prevention Programs in Communities 57858 2New Report Highlights Proven Disease Prevention Programs in Communities 57858 3New Report Highlights Proven Disease Prevention Programs in Communities 57858 4MedImmune Receives U S Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 57856 1MedImmune Receives U S Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 57856 2MedImmune Receives U S Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 57856 3
(Date:12/17/2009)... Jerusalem The Hebrew University of Jerusalem Kuvin ... Diseases has received a $5 million grant from ... into visceral leishmaniasis in Ethiopia. , The project ... vector biologist working at the Institute of Medical ... Medicine. , The project, entitled ,Studies on the ...
(Date:12/17/2009)... on our data, the molecular mechanism of infection employed ... Klemens Rottner, head of the HZI research group "Cytoskeleton ... the current issue of the scientific journal " Cellular ... bacteria. They can live in the presence and absence ... ingestion by humans occurs mainly via contaminated egg dishes ...
(Date:12/17/2009)... one day provide therapeutic options for muscle and bone ... the umbilical cord, just as the blood that goes ... disorders, said University of Pittsburgh School of Medicine researchers ... Journal of Biomedicine and Biotechnology . , Umbilical ... are remarkably stable and might not trigger strong immune ...
(Date:12/17/2009)... him a recluse at times, researcher says , , ... researcher claims he has identified the illness that ... nausea, vomiting, headaches and skin problems for most ... physical diagnoses have been suggested for the illness ... become a virtual recluse for periods of time. ...
(Date:12/17/2009)... the aging inequity , , THURSDAY, Dec. 17 ... gender inequity: Women develop more and deeper wrinkles ... do. , The disadvantage had long been suspected, ... said Dr. Foad Nahai, a plastic surgeon practicing ... Surgery Journal . The study appears in the ...
Breaking Medicine News(10 mins):Health News:Hebrew U. receives $5 million for research on leishmaniasis in Ethiopia 2Health News:Invasion without a stir 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:New Theory Emerges on Darwin's Illness 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3
... charity Diabetes UK will be withdrawing diabetic food from ... //the disuse of diabetic food which they say are ... ,Squash drinks, chocolates, jam and marmalade specially made ... food stores and pharmacies from today. According to the ...
... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
... as transcendental meditation may decrease blood pressure and ... heart disease, according to a report in the ... one of the JAMA/Archives journals. , ... in India, is taught through a standard protocol ...
... it is found that the survival rate of Hodgkin’s disease ... of the study were published in the journal Cancer. //It ... had the best prognosis. There were significant differences existed between ... malignancy of the lymphatic system of the body, which includes ...
... host a week-long meeting on the Codex Committee on ... , becoming the first Asian host for the meeting ... senior Thai official said. ,Dr. Charal Trinvuthipong, ... 350 delegates from 169 member countries of Codex would ...
... of diabetes has taken on alarming proportions in the last two ... loss of millions of lives, according to a recent study. // ... out that China has the largest number of people with diabetes ... over followed by India with with 30 million people affected by ...
Other Medicine News:Health News:Care Workers Need Some Care Too 2Health News:Meditation may Improve Cardiac Risk Factors in Patients with Coronary Heart Disease 2Health News:HD Type Plays an Important Role in the Survival of the Patient 2
... The BD Safety Knife with BD Xstar ... shield that protects the blade in prodedure ... is based on a grind-less process for ... yields outstanding sharpness and consistency. The ...
Electric high speed system....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Prevents formation of microscopic ice crystals and sample distortion caused by slow freezing of hyperosmolar tissue samples in conventional cyrostats....
Medicine Products: